• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

延迟 II 期或更高分期肾细胞癌根治性肾切除术的影响。

The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma.

机构信息

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap 2-dong, Songpa-gu, Seoul, 138-736, Korea.

出版信息

J Cancer Res Clin Oncol. 2012 Sep;138(9):1561-7. doi: 10.1007/s00432-012-1230-2. Epub 2012 May 1.

DOI:10.1007/s00432-012-1230-2
PMID:22547152
Abstract

PURPOSE

To evaluate the impact of surgical waiting time (SWT) on outcomes of patients who underwent radical nephrectomy for stage II or higher renal cell carcinoma (RCC).

METHODS

Of the 1,732 patients who underwent surgery for RCC between 1989 and 2007, medical records of 319 with clinical stage II or higher RCC without distant metastases were retrospectively reviewed. Ten patients with SWT greater than 3 months were excluded from analysis, and we compared pathological upstaging and survival rates between patients with SWT <1 month (234/319, 73.3 %) and 1-3 months (75/319, 23.5 %).

RESULTS

Clinicopathological characteristics between two groups were not different except the presence of symptom. The pathological upstaging was higher in patients with SWT of 1-3 months but statistically not significant. SWT of 1-3 months was not an independent predictor of pathological upstaging, recurrence-free survival (RFS; p = 0.896), or cancer-specific survival (CSS; p = 0.737). On subgroup analysis by TNM stage (cT2NxcM0 and cT3-4NxcM0), SWT of 1-3 months was not an independent predictor of pathological upstaging and was not associated with RFS or CSS. SWT, treated as a continuous variable, was also not an independent predictor of outcome in any subgroup. Similar results were found in symptomatic patients.

CONCLUSIONS

The outcomes of patients with prolonged SWT did not differ from those of most patients who underwent nephrectomy within 1 month. In patients with stage II or higher RCC who underwent nephrectomy within 3 months after diagnosis, prolonged SWT was not an independent predictor of pathological upstaging, RFS, or CSS.

摘要

目的

评估手术等待时间(SWT)对接受根治性肾切除术治疗 II 期或更高分期肾细胞癌(RCC)患者结局的影响。

方法

在 1989 年至 2007 年间接受 RCC 手术的 1732 名患者中,回顾性分析了 319 名临床分期 II 期或更高分期且无远处转移的 RCC 患者的病历。排除 SWT 大于 3 个月的 10 名患者,比较 SWT<1 个月(234/319,73.3%)和 1-3 个月(75/319,23.5%)的患者的病理升级和生存率。

结果

两组的临床病理特征除症状外无差异。SWT 为 1-3 个月的患者病理升级率较高,但无统计学意义。SWT 为 1-3 个月不是病理升级的独立预测因素,与无复发生存率(RFS;p=0.896)或癌症特异性生存率(CSS;p=0.737)无关。按 TNM 分期(cT2NxcM0 和 cT3-4NxcM0)进行亚组分析,SWT 为 1-3 个月不是病理升级的独立预测因素,也与 RFS 或 CSS 无关。SWT 作为连续变量也不能预测任何亚组的结局。在有症状的患者中也得到了类似的结果。

结论

SWT 延长的患者结局与大多数在 1 个月内接受肾切除术的患者无差异。在诊断后 3 个月内接受肾切除术的 II 期或更高分期 RCC 患者中,SWT 延长不是病理升级、RFS 或 CSS 的独立预测因素。

相似文献

1
The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma.延迟 II 期或更高分期肾细胞癌根治性肾切除术的影响。
J Cancer Res Clin Oncol. 2012 Sep;138(9):1561-7. doi: 10.1007/s00432-012-1230-2. Epub 2012 May 1.
2
Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy.局限性肾部分切除术后偶然发现的病理T3a期小肾癌患者的肿瘤学结局
J Cancer Res Clin Oncol. 2016 Jul;142(7):1651-7. doi: 10.1007/s00432-016-2172-x. Epub 2016 May 19.
3
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.部分肾切除术与根治性肾切除术治疗 T1b 和 T2 期临床肾肿瘤的比较:系统评价和荟萃分析。
Eur Urol. 2017 Apr;71(4):606-617. doi: 10.1016/j.eururo.2016.08.060. Epub 2016 Sep 7.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
Partial nephrectomy versus radical nephrectomy for clinical localised renal masses.临床局限性肾肿块的部分肾切除术与根治性肾切除术对比
Cochrane Database Syst Rev. 2017 May 9;5(5):CD012045. doi: 10.1002/14651858.CD012045.pub2.
6
Comparison of survival and renal function between partial and radical laparoscopic nephrectomy for T1b renal cell carcinoma.部分腹腔镜与根治性腹腔镜肾切除术治疗 T1b 期肾癌的生存及肾功能比较。
J Cancer Res Clin Oncol. 2020 Jan;146(1):261-272. doi: 10.1007/s00432-019-03058-z. Epub 2019 Nov 1.
7
Cytoreductive nephrectomy in metastatic renal cell carcinoma.细胞减灭性肾切除术治疗转移性肾细胞癌。
Cochrane Database Syst Rev. 2024 Jun 7;6(6):CD013773. doi: 10.1002/14651858.CD013773.pub2.
8
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者,在重建下肢节段性切除时,采用带血管游离腓骨移植来增强照射后的自体骨移植,其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当?
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.
9
The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma.年龄调整 Charlson 共病指数作为手术治疗非转移性透明细胞肾细胞癌总生存的预测因子。
J Cancer Res Clin Oncol. 2020 Jan;146(1):187-196. doi: 10.1007/s00432-019-03042-7. Epub 2019 Oct 12.
10
A comparison of open, laparoscopic, and robotic radical nephrectomy with tumor thrombectomy from the intercontinental collaboration on renal cell carcinoma.来自肾细胞癌洲际合作组织的开放性、腹腔镜及机器人辅助根治性肾切除术联合肿瘤血栓切除术的比较
J Robot Surg. 2025 Jun 4;19(1):269. doi: 10.1007/s11701-025-02424-z.

引用本文的文献

1
Impact of Time-To-Surgery on the Prognosis of Patients with T1 Renal Cell Carcinoma: Implications for the COVID-19 Pandemic.手术时间对T1期肾细胞癌患者预后的影响:对COVID-19大流行的启示
J Clin Med. 2022 Dec 19;11(24):7517. doi: 10.3390/jcm11247517.
2
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.COVID-19大流行期间泌尿生殖系统癌症不断发展的临床管理
Front Oncol. 2021 Sep 27;11:734963. doi: 10.3389/fonc.2021.734963. eCollection 2021.
3
Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC.

本文引用的文献

1
Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.术前靶向治疗转移性肾细胞癌的安全性。
Eur Urol. 2011 Nov;60(5):964-71. doi: 10.1016/j.eururo.2011.05.032. Epub 2011 May 25.
2
The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach?靶向治疗在肾细胞癌(RCC)中的新作用:现在是采用新辅助治疗还是辅助治疗方法的时机?
Crit Rev Oncol Hematol. 2012 Feb;81(2):151-62. doi: 10.1016/j.critrevonc.2011.02.003. Epub 2011 Mar 8.
3
How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes?
从诊断起肾切除延迟超过10周与pT3期肾细胞癌的总生存期降低相关。
J Kidney Cancer VHL. 2021 Jun 14;8(2):27-33. doi: 10.15586/jkcvhl.v8i2.125. eCollection 2021.
4
What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.2019冠状病毒病时期的择期肿瘤手术是什么?关于手术延迟对癌症患者预后影响的文献综述
Clin Oncol Res. 2020 Jun;3(6):1-11. doi: 10.31487/j.COR.2020.06.05. Epub 2020 Jun 26.
5
Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic.局部和转移性肾细胞癌延迟手术:COVID-19 大流行的系统评价和荟萃分析。
World J Urol. 2021 Dec;39(12):4295-4303. doi: 10.1007/s00345-021-03734-1. Epub 2021 May 24.
6
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond.在 COVID-19 时代及以后,延迟 T1b-T2bN0M0 期肾细胞癌的手术治疗:肿瘤学意义。
Urol Oncol. 2021 May;39(5):247-257. doi: 10.1016/j.urolonc.2020.10.012. Epub 2020 Oct 20.
7
Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses: Implications for Critical Clinical Decision-making During the COVID-19 Pandemic.手术延迟与 T2 期肾肿瘤患者总生存的关系:COVID-19 大流行期间对关键临床决策的启示。
Urology. 2021 Jan;147:50-56. doi: 10.1016/j.urology.2020.09.010. Epub 2020 Sep 20.
8
Urologic oncology practice during COVID-19 pandemic: A systematic review on what can be deferrable vs. nondeferrable.COVID-19 大流行期间的泌尿肿瘤学实践:关于可推迟与不可推迟的系统评价。
Urol Oncol. 2020 Oct;38(10):783-792. doi: 10.1016/j.urolonc.2020.06.028. Epub 2020 Jun 26.
9
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.延迟肾切除术对直径大于4cm肾肿瘤患者肿瘤学结局的影响。
Urol Oncol. 2016 May;34(5):239.e1-8. doi: 10.1016/j.urolonc.2015.12.001. Epub 2016 Jan 12.
肾细胞癌患者在不影响病理结果的情况下可以等待多久进行手术?
Can Urol Assoc J. 2011 Dec;5(6):E148-51. doi: 10.5489/cuaj.10035. Epub 2011 Mar 1.
4
Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance.肾脏肿块的生长动力学:行主动监测的前瞻性队列患者分析。
Eur Urol. 2011 May;59(5):863-7. doi: 10.1016/j.eururo.2011.02.023. Epub 2011 Feb 22.
5
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study.瑞典前列腺癌登记随访研究中,初始根治性前列腺切除术与延期根治性前列腺切除术的结果比较。
J Urol. 2010 Oct;184(4):1322-7. doi: 10.1016/j.juro.2010.06.008. Epub 2010 Aug 17.
6
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.术前舒尼替尼治疗肾细胞癌的前瞻性临床试验。
J Urol. 2010 Sep;184(3):859-64. doi: 10.1016/j.juro.2010.05.041.
7
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.美国癌症联合委员会:第 7 版 AJCC 癌症分期手册与 TNM 的未来。
Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4.
8
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.索拉非尼新辅助临床试验用于 II 期或更高分期的肾细胞癌患者。
J Clin Oncol. 2010 Mar 20;28(9):1502-7. doi: 10.1200/JCO.2009.24.7759. Epub 2010 Feb 16.
9
Neoadjuvant treatment of renal cell carcinoma.肾细胞癌的新辅助治疗。
Urol Oncol. 2010 Jan-Feb;28(1):69-73. doi: 10.1016/j.urolonc.2009.02.001.
10
Value of frozen section analysis of enlarged lymph nodes during radical nephrectomy for renal cell carcinoma.肾细胞癌根治性肾切除术中肿大淋巴结冰冻切片分析的价值
Urology. 2009 Aug;74(2):364-8. doi: 10.1016/j.urology.2008.12.075. Epub 2009 Apr 10.